HER2 Therapy — An Abundance of Riches

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a distinct subset of breast cancer characterized by overexpression of the HER2 protein. Clinically, HER2-positive tumors are associated with a more aggressive phenotype and poor outcomes. With the introduction of trastuzumab, a humanized monoclonal antibody targeting HER2, significant improvements in survival were observed in patients with HER2-positive metastatic breast cancer and in patients with early-stage disease.1,2 Despite the practice-changing impact of trastuzumab and the substantial improvement in outcomes, patients with HER2-positive metastatic breast cancer ultimately die from the disease.A number of strategies have been developed to deal with . . .